Loading...
XWAR
MOC
Market cap45mUSD
Jul 25, Last price  
7.93PLN
1D
10.29%
1Q
-7.25%
IPO
-72.65%
Name

Molecure SA

Chart & Performance

D1W1MN
P/E
P/S
1,633,833.76
EPS
Div Yield, %
Shrs. gr., 5y
4.24%
Rev. gr., 5y
-49.35%
Revenues
0k
-99.99%
5,4006,6006,0003,0002,807122,936,4004001,613,238100
Net income
-18m
L+35.22%
-559,106-2,424,293-2,404,332-3,777,159-4,246,83267,962,632-13,642,556-13,539,992-18,308,202
CFO
-57m
L+380.55%
-1,530,239-1,440,683-599,630-4,889,462-7,107,93657,435,477-13,496,417-10,213,383-11,859,317-56,990,319

Profile

Molecure S.A., a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for the treatment of neoplastic and inflammatory diseases in Poland. It is involved in the development of OATD-01, a chitotriosidase/acidic mammalian chitinase inhibitor that has completed phase I clinical trial for the treatment of idiopathic pulmonary fibrosis and sarcoidosis; YKL-40 program for the treatment of cancer and fibrosis; OATD-02 for the treatment of cancer; and Deubiquitinase program. The company was formerly known as OncoArendi Therapeutics S.A. and changed its name to Molecure S.A. in March 2022. Molecure S.A. was founded in 2012 and is headquartered in Warsaw, Poland.
IPO date
Apr 19, 2018
Employees
109
Domiciled in
PL
Incorporated in
PL

Valuation

Title
PLN in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
100
-99.99%
1,613
403,209.50%
Cost of revenue
1,646
9,380
Unusual Expense (Income)
NOPBT
(1,646)
(7,767)
NOPBT Margin
Operating Taxes
(1,724)
Tax Rate
NOPAT
(1,646)
(6,043)
Net income
(18,308)
35.22%
(13,540)
-0.75%
Dividends
Dividend yield
Proceeds from repurchase of equity
29,716
49,100
117
BB yield
-14.96%
-0.06%
Debt
Debt current
2,182
2,164
2,205
Long-term debt
12,283
12,115
10,611
Deferred revenue
104
142
Other long-term liabilities
42
326
289
Net debt
(3,723)
(49,709)
(52,802)
Cash flow
Cash from operating activities
(56,990)
(11,859)
(10,213)
CAPEX
(655)
(362)
(33,631)
Cash from investing activities
(23,571)
(44,507)
(33,586)
Cash from financing activities
34,761
54,736
7,377
FCF
(28,124)
3,975
(2,721)
Balance
Cash
18,188
63,988
65,618
Long term investments
Excess cash
18,188
63,988
65,537
Stockholders' equity
(81,078)
6,522
126,448
Invested Capital
191,865
158,177
67,290
ROIC
ROCE
EV
Common stock shares outstanding
16,836
14,030
Price
10.10
-48.21%
19.50
36.75%
14.26
-61.87%
Market cap
328,302
64.10%
200,068
-61.66%
EV
278,593
147,266
EBITDA
3,820
202
(6,453)
EV/EBITDA
1,377.00
Interest
38
16
Interest/NOPBT